A Phase II Study of Neoadjuvant Opnurasib KRAS G12C Inhibitor in Patients With Surgically Resectable Non-Small Cell Lung Cancer (CCTG IND.242A): A Substudy of the IND.242 Platform Master Protocol
| Autor: | Spicer, J., Blais, N., Owen, S., Robinson, A.G., Chu, Q., Labbe, C., Shieh, B., Brown-Walker, P., Sederias, J., Jensen, K., Farago, A.F., Tsao, M.-S., Cottrell, T.R., Kidane, B., Laurie, S., Juergens, R., Bradbury, P.A., Tu, W., Gaudreau, P.-O. |
|---|---|
| Zdroj: | In Clinical Lung Cancer September 2024 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect